Liu S, Sylvester D M
Pharmacology/Toxicology Program, College of Pharmacy, Washington State University, Pullman 99163-6510.
Thromb Res. 1992 Sep 1;67(5):533-44. doi: 10.1016/0049-3848(92)90014-2.
Tetrahydroacridine (THA), or Cognex, is currently awaiting FDA approval for the treatment of Alzheimer's disease. In addition to reports indicating that THA improves the symptoms of patients with Alzheimer's disease, we have found that THA possesses potent antiplatelet activity. THA produced dose-dependent inhibition of human platelet aggregation induced by collagen, ADP, A23187, and phorbol ester. THA, when added to activated platelets, dispersed the platelet aggregates. We have also examined the effects of THA on intracellular Ca++ mobilization, ATP release, and production of cyclic AMP.
四氢吖啶（THA），即益智药，目前正等待美国食品药品监督管理局（FDA）批准用于治疗阿尔茨海默病。除了有报告表明THA可改善阿尔茨海默病患者的症状外，我们还发现THA具有强大的抗血小板活性。THA对胶原蛋白、ADP、A23187和佛波酯诱导的人血小板聚集产生剂量依赖性抑制作用。当将THA添加到活化的血小板中时，可使血小板聚集体分散。我们还研究了THA对细胞内钙离子动员、ATP释放和环磷酸腺苷生成的影响。
